Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.26. Hemispherx BioPharma shares last traded at $0.24, with a volume of 118,947 shares.
Hemispherx BioPharma Stock Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- How to Evaluate a Stock Before Buying
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 11/4 – 11/8
- What Is WallStreetBets and What Stocks Are They Targeting?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
